Hope for stubborn skin rash: existing drug tested for Hard-to-Treat eczema
NCT ID NCT04600362
Summary
This study is testing whether an existing medication called dupilumab (brand name Dupixent) can help people with nummular eczema, a chronic, itchy skin rash that is often difficult to treat. The trial will involve 70 adults with moderate-to-severe cases to see if the drug reduces the rash area and severity over 16 weeks. Researchers are hopeful because the drug works on similar inflammation pathways as another type of eczema it already treats.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NUMMULAR ECZEMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Klinikum re. Isar Dermatology
München, Bavaria, 81675, Germany
Conditions
Explore the condition pages connected to this study.